Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
April 09, 2024 15:34 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
April 08, 2024 11:36 ET
|
Revolution Medicines, Inc.
Two original papers in Nature highlight the discovery and translational implications of RMC-7977, a RAS(ON) multi-selective tri-complex inhibitor that exhibits unprecedented anti-tumor activity in...
Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes
April 02, 2024 08:00 ET
|
Fractyl Health, Inc.
Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation
OMNIQ ANNOUNCES 2023 REVENUE OF $81.4 MILLION
April 01, 2024 17:11 ET
|
OMNIQ Corp.
SALT LAKE CITY, April 01, 2024 (GLOBE NEWSWIRE) -- OMNIQ Corp. (NASDAQ: OMQS) (“OMNIQ” or the “Company”), a provider of Artificial Intelligence (AI) and IoT–based solutions will release Full Year...
Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
April 01, 2024 07:00 ET
|
Fractyl Health, Inc.
Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs
April 01, 2024 06:00 ET
|
Fractyl Health, Inc.
Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs
Thor Equities Group and Vesper Holdings Launch Student Housing Joint Venture
March 20, 2024 14:38 ET
|
Thor Equities Group
New York, NY, March 20, 2024 (GLOBE NEWSWIRE) -- Thor Equities Group and Vesper Holdings, leaders in real estate development and investment, are pleased to announce the launch of a joint venture...
Stephen Samuel Transforms Industries: From Premier Pharmacy Services to Evolve Realty & Development Corp.
March 18, 2024 17:27 ET
|
Evolve Realty & Development
BEVERLY HILLS, CA, March 18, 2024 (GLOBE NEWSWIRE) -- In a dynamic business world where adaptability and vision are the keys to lasting success, Stephen Samuel stands out as a transformative figure....
New Poll Shows Arizonans Want Action on Homelessness
March 18, 2024 13:40 ET
|
The Cicero Institute
Phoenix, AZ, March 18, 2024 (GLOBE NEWSWIRE) -- New findings in a survey of Arizona voters, commissioned by the Cicero Institute, show Arizona voters are deeply concerned about the rise in...
Veteran Entrepreneur Stephen Samuel to Spearhead Evolve Realty & Development Corp.
March 14, 2024 17:55 ET
|
Evolve Realty & Development
BEVERLY HILLS, CA, March 14, 2024 (GLOBE NEWSWIRE) -- After founding a niche pharmaceutical services company and building it into one of the largest sector players in the western United States,...